Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials (Q38318950)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials |
scientific article |
Statements
1 reference
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials (English)
1 reference
Keikawus Arastéh
1 reference
Hans-Jürgen Stellbrink
1 reference
Jean-François Delfraissy
1 reference
Bonaventura Clotet
1 reference
Julio S G Montaner
1 reference
Joseph J Eron
1 reference
Sharon L Walmsley
1 reference
Daniel R Kuritzkes
1 reference
Peter J Piliero
1 reference
Lynn Smiley
1 reference
Calvin Cohen
1 reference
Jacob P Lalezari
1 reference
Lucille Donatacci
1 reference
Joep Lange
1 reference
Neil E Buss
1 reference
Mark Nelson
1 reference
David A Cooper
1 reference
Keith Henry
1 reference
Mary O'Hearn
1 reference
Jacques Reynes
1 reference
Benoit Trottier
1 reference
Cynthia Wat
1 reference
Martin Wilkinson
1 reference
Adeline Valentine
1 reference
Denise Guimaraes
1 reference
Ralph Demasi
1 reference
Jain Chung
1 reference
Miklos P Salgo
1 reference
1 December 2005
1 reference
1 reference
40
1 reference
4
1 reference
404-412
1 reference
Identifiers
1 reference
1 reference